Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1 (2002)
- Authors:
- USP affiliated authors: BARONE, ANTONIO ALCI - FM ; CARRILHO, FLAIR JOSE - FM
- Unidade: FM
- Subjects: HEPATOPATIAS; GASTROENTEROLOGIA
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2002
- Source:
- Título: Hepatology/ Official Journal of the American for the Study of Liver Diseases
- Volume/Número/Paginação/Ano: v. 36, n. 4
- Conference titles: AASLD Annual Meeting and Postgraduate Courses
-
ABNT
BRANDÃO, C. E. et al. Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 11 fev. 2026. , 2002 -
APA
Brandão, C. E., Perez-Gomez, R., Pessoa, M. G., Oliveira-Martinez, M. A., Caramori, C., Bazan-Perez, C. V., et al. (2002). Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Brandão CE, Perez-Gomez R, Pessoa MG, Oliveira-Martinez MA, Caramori C, Bazan-Perez CV, Patelli M, Torres-Ibarra R, Barone A, Dehesa-Violante M, Carrilho F, Vivar R, Tasch F. Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2026 fev. 11 ] -
Vancouver
Brandão CE, Perez-Gomez R, Pessoa MG, Oliveira-Martinez MA, Caramori C, Bazan-Perez CV, Patelli M, Torres-Ibarra R, Barone A, Dehesa-Violante M, Carrilho F, Vivar R, Tasch F. Prospective evaluation of early virological response associated with peginterferon alfa-2 (40KD) (Pegasys(r)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2026 fev. 11 ] - Avaliação prospectiva da resposta virológica precoce associada a terapia com interferon peguilado alfa-2A (pegasys) e ribavirina em estudo randomizado e controlado de pacientes com hepatite crônica C, genótipo 1, que examina 24 vs. 48 semanas de tratamento
- Pegylated interferon for chronic HCV infection: is it that good for "real real-life"?
- Resultados de eficácia e segurança de estudo multicêntrico, prospectivo, randomizado e controlado comparando a combinação PEG IFN alfa-2A (pegasys) e ribavirina (copegus) administrados por 24 vs 48 semanas em pacientes com hepatite crônica (HCG) genótipo 1 virgens de tratamento
- Uniformização de política para acompanhamento de tratamento das hepatites virais B e C no Estado de São Paulo
- Weigt-based combination therapy with peginterferon alfa 2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C
- Patients with chronic hepatitis C and normal transaminases
- Antifibrotic therapy in chronic hepatitis C
- Infecções hospitalares em 46 pacientes submetidos a artoplastia total do quadril.
- Infectologistas debatem subespecialidades e epidemias
- Toxoplasmose
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
